Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Scientists test 'Living Drug' to halt diabetes attack

NCT ID NCT07395050

Summary

This is a very early safety study testing a new cell therapy for people recently diagnosed with Type 1 diabetes. Researchers will collect a patient's own immune cells, modify them in a lab to target the cells that attack the pancreas, and then infuse them back. The main goal is to see if this process is safe and feasible for six adults aged 18-35 who were diagnosed within the last two years.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for STAGE 3 TYPE 1 DIABETES are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.